1
|
Visram A, De La Torre A, White D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, McCurdy A, LeBlanc R, Song K, Mian H, Louzada M, Sebag M, Bergstrom D, Stakiw J, Reiman A, Kotb R, Aslam M, Venner C, Kaedbey R, Gul E, Reece D. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database. Blood Cancer J 2023; 13:181. [PMID: 38065967 PMCID: PMC10709576 DOI: 10.1038/s41408-023-00946-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Revised: 10/09/2023] [Accepted: 11/07/2023] [Indexed: 12/18/2023] Open
Abstract
Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort. Overall, 663 patients had disease progression on anti-CD38 mAb therapy, 466 received further treatment (346 with SoC regimens were included, 120 with investigational agents on clinical trial and were excluded). The median age at initiation of subsequent SoC therapy of 67.9 (range 39.6-89.6) years with a median of 3 prior lines (range 1-9). The median PFS and OS from the start of subsequent therapy was 4.6 (95% CI 4.1-5.6) months and 13.3 (95% CI 10.6-16.6) months, respectively. The median PFS and OS of patients with TCR disease (n = 199) was 4.4 (95% CI 3.6-5.3) months and 10.5 (95% CI 8.5-13.8) months. Our results reinforce that real-world patients with relapsed MM, particularly those with TCR disease, have dismal outcomes. There remains an urgent unmet need for the development of and access to effective therapeutics for these patients.
Collapse
Affiliation(s)
- A Visram
- Department of Medicine, The Ottawa Hospital, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | - A De La Torre
- Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
| | - D White
- Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
| | - J Su
- Canadian Myeloma Research Group, Toronto, ON, Canada
| | - E Masih-Khan
- Canadian Myeloma Research Group, Toronto, ON, Canada
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - M Chu
- Department of Oncology, Cross Cancer Institute, Edmonton, Alberta, Edmonton, AB, Canada
| | - V Jimenez-Zepeda
- Tom Baker Cancer Center, Department of Hematology, University of Calgary, Calgary, AB, Canada
| | - A McCurdy
- Department of Medicine, The Ottawa Hospital, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | - R LeBlanc
- Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
| | - K Song
- The Leukemia/Bone Marrow Transplant Program of BC, British Columbia Cancer Agency, Vancouver, Canada
| | - H Mian
- Juravinski Cancer Centre (Hamilton-CCO), Hamilton, ON, Canada
| | - M Louzada
- University of Western Ontario, London Health Sciences Centre, London, ON, Canada
| | - M Sebag
- Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
| | - D Bergstrom
- Division of Hematology, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada
| | - J Stakiw
- Saskatoon Cancer Centre, Saskatoon, SK, Canada
| | - A Reiman
- Oncology, Saint John Regional Hospital, Saint John, NB, Canada
| | - R Kotb
- Medical Oncology and Hematology, Cancer Care Manitoba, Winnipeg, MB, Canada
| | - M Aslam
- Allan Blair Cancer Center, Regina, SK, Canada
| | - C Venner
- BC Cancer - Vancouver Centre, Lymphoma and Myeloma Program, University of British Columbia, Vancouver, BC, Canada
| | - R Kaedbey
- Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Montreal, QC, Canada
| | - E Gul
- Canadian Myeloma Research Group, Toronto, ON, Canada
| | - D Reece
- Canadian Myeloma Research Group, Toronto, ON, Canada.
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
| |
Collapse
|
2
|
Cajander N, Reiman A, Tappura S. Occupational safety and health and temporary agency work in multiemployer restaurants. Work 2023:WOR220033. [PMID: 36710697 DOI: 10.3233/wor-220033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND Current occupational safety and health (OSH) literature calls for sociotechnical, system-level approaches that increase understanding of the underlying reasons for insufficient OSH performance in non-standard employment that is associated with lower labour and social security protection when compared with traditional forms of work. OBJECTIVE This study focused on temporary agency work (TAW) which is a central form of nonstandard employment. The objective was to explore OSH issues in temporary agency work (TAW) in small and medium -sized multiemployer restaurants in Finland and discuss the issues from the perspectives of the agency worker, user company and agency. METHODS A directed content analysis method was used to examine the data obtained from semi-structured interviews (n = 20) with agency workers, restaurant managers and experts representing the temporary work agencies, a pension insurer, and a labour union. The balanced work system theory was used as a framework for this qualitative analysis. RESULTS A variety of OSH risks and hazards in TAW were identified. In addition, the complexity of OSH management was highlighted in this triangular employment relationship between the agency worker, the user company, and the agency. CONCLUSION This study reveals problems related to OSH in TAW. Restaurants are entities separate from agencies, so establishing and adhering to a common process of OSH management is not simple.
Collapse
Affiliation(s)
- Niko Cajander
- Industrial Engineering and Management, University of Oulu, Oulu, Finland
| | - A Reiman
- Industrial Engineering and Management, University of Oulu, Oulu, Finland
| | | |
Collapse
|
3
|
Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2018; 29:1074. [PMID: 28541409 DOI: 10.1093/annonc/mdx160] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Gates DA, Anderson D, Anderson S, Zarnstorff M, Spong DA, Weitzner H, Neilson GH, Ruzic D, Andruczyk D, Harris JH, Mynick H, Hegna CC, Schmitz O, Talmadge JN, Curreli D, Maurer D, Boozer AH, Knowlton S, Allain JP, Ennis D, Wurden G, Reiman A, Lore JD, Landreman M, Freidberg JP, Hudson SR, Porkolab M, Demers D, Terry J, Edlund E, Lazerson SA, Pablant N, Fonck R, Volpe F, Canik J, Granetz R, Ware A, Hanson JD, Kumar S, Deng C, Likin K, Cerfon A, Ram A, Hassam A, Prager S, Paz-Soldan C, Pueschel MJ, Joseph I, Glasser AH. Stellarator Research Opportunities: A Report of the National Stellarator Coordinating Committee. J Fusion Energ 2018. [DOI: 10.1007/s10894-018-0152-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
5
|
Weller A, Sakakibara S, Watanabe KY, Toi K, Geiger J, Zarnstorff MC, Hudson SR, Reiman A, Werner A, Nührenberg C, Ohdachi S, Suzuki Y, Yamada H. Significance of MHD Effects in Stellarator Confinement. Fusion Science and Technology 2017. [DOI: 10.13182/fst06-a1231] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Weller
- Max-Planck-Institut für Plasmaphysik, EURATOM-IPP Association, D-17491 Greifswald, Germany
| | - S. Sakakibara
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Y. Watanabe
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - K. Toi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - J. Geiger
- Max-Planck-Institut für Plasmaphysik, EURATOM-IPP Association, D-17491 Greifswald, Germany
| | | | - S. R. Hudson
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543
| | - A. Reiman
- Princeton Plasma Physics Laboratory, Princeton, NJ 08543
| | - A. Werner
- Max-Planck-Institut für Plasmaphysik, EURATOM-IPP Association, D-17491 Greifswald, Germany
| | - C. Nührenberg
- Max-Planck-Institut für Plasmaphysik, EURATOM-IPP Association, D-17491 Greifswald, Germany
| | - S. Ohdachi
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - Y. Suzuki
- National Institute for Fusion Science, Toki 509-5292, Japan
| | - H. Yamada
- National Institute for Fusion Science, Toki 509-5292, Japan
| | | | | |
Collapse
|
6
|
Fu GY, Isaev M, Ku LP, Mikhailov M, Redi MH, Sanchez R, Subbotin A, Cooper WA, Hirshman SP, Monticello DA, Reiman A, Zarnstorff M. Ideal Magnetohydrodynamic Stability of the NCSX. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1300] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- G. Y. Fu
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - M. Isaev
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - L. P. Ku
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | | | - M. H. Redi
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - R. Sanchez
- >Universidad Carlos III de Madrid, Madrid, Spain
| | | | - W. A. Cooper
- >CRPP0EPFL, Association Euratom-Suisse, Lausanne, Switzerland
| | | | - D. A. Monticello
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - A. Reiman
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - M. Zarnstorff
- >Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| |
Collapse
|
7
|
Reiman A, Hirshman S, Hudson S, Monticello D, Rutherford P, Boozer A, Brooks A, Hatcher R, Ku L, Lazarus EA, Neilson H, Strickler D, White R, Zarnstorff M. Equilibrium and Flux Surface Issues in the Design of the NCSX. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1296] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Reiman
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - S. Hirshman
- Oak Ridge National Laboratory, P.O. Box 2009, Oak Ridge, Tennessee 37831
| | - S. Hudson
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - D. Monticello
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - P. Rutherford
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - A. Boozer
- Columbia University, New York, New York 10027
| | - A. Brooks
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - R. Hatcher
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - L. Ku
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - E. A. Lazarus
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - H. Neilson
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - D. Strickler
- Oak Ridge National Laboratory, P.O. Box 2009, Oak Ridge, Tennessee 37831
| | - R. White
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - M. Zarnstorff
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| |
Collapse
|
8
|
Pomphrey N, Boozer A, Brooks A, Hatcher R, Hirshman SP, Hudson S, Ku LP, Lazarus EA, Mynick H, Monticello D, Redi M, Reiman A, Zarnstorff MC, Zatz I. NCSX Magnetic Configuration Flexibility and Robustness. Fusion Science and Technology 2017. [DOI: 10.13182/fst07-a1298] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Pomphrey
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - A. Boozer
- Columbia University, New York, New York 10027
| | - A. Brooks
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - R. Hatcher
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - S. P. Hirshman
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - S. Hudson
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - L. P. Ku
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - E. A. Lazarus
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831
| | - H. Mynick
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - D. Monticello
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - M. Redi
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - A. Reiman
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - M. C. Zarnstorff
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| | - I. Zatz
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08540
| |
Collapse
|
9
|
Musto P, Anderson K, Attal M, Richardson P, Badros A, Hou J, Comenzo R, Du J, Durie B, San Miguel J, Einsele H, Chen W, Garderet L, Pietrantuono G, Hillengass J, Kyle R, Moreau P, Lahuerta J, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy P, Nouel A, Rajkumar S, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss B, Palumbo A. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017; 28:228-245. [DOI: 10.1093/annonc/mdw606] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
10
|
Seymour L, Le Teuff G, Tsao M, Brambilla E, Shepherd F, Soria J, Kratzke R, Graziano S, Douillard J, Rosell R, Reiman A, Lacas B, Bourredjem A, Le Chevalier T, Pirker R, Filipits M, Hainaut P, Janne P, Pignon J. Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BGM, Miguel JFS. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28:525-42. [PMID: 24253022 PMCID: PMC4143389 DOI: 10.1038/leu.2013.350] [Citation(s) in RCA: 182] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2013] [Revised: 10/23/2013] [Accepted: 11/07/2013] [Indexed: 01/08/2023]
Abstract
Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their combinations target specific aspects of the biology of tumor cells. Multiple myeloma (MM) has become one of the best examples in this regard, reflected in the identification of new pathogenic mechanisms, together with the development of novel drugs that are being explored from the preclinical setting to the early phases of clinical development. We review the biological rationale for the use of the most important new agents for treating MM and summarize their clinical activity in an increasingly busy field. First, we discuss data from already approved and active agents (including second- and third-generation proteasome inhibitors (PIs), immunomodulatory agents and alkylators). Next, we focus on agents with novel mechanisms of action, such as monoclonal antibodies (MoAbs), cell cycle-specific drugs, deacetylase inhibitors, agents acting on the unfolded protein response, signaling transduction pathway inhibitors and kinase inhibitors. Among this plethora of new agents or mechanisms, some are specially promising: anti-CD38 MoAb, such as daratumumab, are the first antibodies with clinical activity as single agents in MM. Moreover, the kinesin spindle protein inhibitor Arry-520 is effective in monotherapy as well as in combination with dexamethasone in heavily pretreated patients. Immunotherapy against MM is also being explored, and probably the most attractive example of this approach is the combination of the anti-CS1 MoAb elotuzumab with lenalidomide and dexamethasone, which has produced exciting results in the relapsed/refractory setting.
Collapse
Affiliation(s)
- E M Ocio
- Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca-IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain
| | - P G Richardson
- Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - S V Rajkumar
- Department of Hematology, Mayo Clinic, Rochester, MN, USA
| | - A Palumbo
- Department of Hematology, University of Torino, Torino, Italy
| | - M V Mateos
- Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca-IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain
| | - R Orlowski
- Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA
| | - S Kumar
- Department of Hematology, Mayo Clinic, Rochester, MN, USA
| | - S Usmani
- M.I.R.T. UAMS, Little Rock, AR, USA
| | - D Roodman
- Director of Hematology/Oncology, Indiana University, Indianapolis, IN, USA
| | - R Niesvizky
- Department of Hematology, Weill Cornell Medical College, New York, NY, USA
| | - H Einsele
- Department of Internal Medicine, University of Wurzburg, Wurzburg, Germany
| | - K C Anderson
- Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
| | - M A Dimopoulos
- School of Medicine, University of Athens, Athens, Greece
| | - H Avet-Loiseau
- Department of Hematology, University of Toulouse, Toulouse, France
| | - U-H Mellqvist
- Department of Medicine, Section of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - I Turesson
- Department of Medicine, Section of Hematology, Skane University Hospital, Malmo, Sweden
| | - G Merlini
- Department of Molecular Medicine, Univeristy of Pavia, Pavia, Italy
| | - R Schots
- Department of Clinical Hematology and Stem Cell Laboratory, University Ziekenhuis, Brussels, Belgium
| | - P McCarthy
- Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - L Bergsagel
- Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA
| | - C S Chim
- Department of Hematology, Queen Mary Hospital, Hong Kong
| | - J J Lahuerta
- Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J Shah
- Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA
| | - A Reiman
- Department of Oncology, University of New Brunswick, Saint John Regional Hospital, St John, NB, Canada
| | - J Mikhael
- Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA
| | - S Zweegman
- Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
| | - S Lonial
- Department of Hematology and Medical Oncology, Shanghai Chang Zheng Hospital, Atlanta, GA, USA
| | - R Comenzo
- Department of Hematology, Tufts Medical School, Boston, MA, USA
| | - W J Chng
- Department of Hematology Oncology, National University Cancer Institute, Singapore
| | - P Moreau
- Department of Hematology, University Hospital, Nantes, France
| | - P Sonneveld
- Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
| | - H Ludwig
- Department of Medicine, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria
| | | | - J F S Miguel
- 1] Department of Hematology, University Hospital and Cancer Research Center, University of Salamanca-IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain [2] Department of Clinical and Translational Medicine, University of Navarra, Pamplona, Spain
| |
Collapse
|
12
|
Pablant NA, Bitter M, Delgado-Aparicio L, Goto M, Hill KW, Lazerson S, Morita S, Roquemore AL, Gates D, Monticello D, Nielson H, Reiman A, Reinke M, Rice JE, Yamada H. Layout and results from the initial operation of the high-resolution x-ray imaging crystal spectrometer on the Large Helical Device. Rev Sci Instrum 2012; 83:083506. [PMID: 22938293 DOI: 10.1063/1.4744935] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
First results of ion and electron temperature profile measurements from the x-ray imaging crystal spectrometer (XICS) diagnostic on the Large Helical Device (LHD) are presented. This diagnostic system has been operational since the beginning of the 2011 LHD experimental campaign and is the first application of the XICS diagnostic technique to helical plasma geometry. The XICS diagnostic provides measurements of ion and electron temperature profiles in LHD with a spatial resolution of 2 cm and a maximum time resolution of 5 ms (typically 20 ms). Ion temperature profiles from the XICS diagnostic are possible under conditions where charge exchange recombination spectroscopy (CXRS) is not possible (high density) or is perturbative to the plasma (low density or radio frequency heated plasmas). Measurements are made by using a spherically bent crystal to provide a spectrally resolved 1D image of the plasma from line integrated emission of helium-like Ar(16 +). The final hardware design and configuration are detailed along with the calibration procedures. Line-integrated ion and electron temperature measurements are presented, and the measurement accuracy is discussed. Finally central temperature measurements from the XICS system are compared to measurements from the Thomson scattering and CXRS systems, showing excellent agreement.
Collapse
Affiliation(s)
- N A Pablant
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Kanerva M, Ollgren J, Lyytikainen O, Agthe N, Mottonen T, Kauppinen M, Laurila K, Suomalainen P, Vuorela R, Ryhta I, Vastamaki R, Helen M, Hietaniemi K, Varis T, Eliin L, Nieminen J, Skogberg K, Salminen R, Yrjonsalo ML, Kimmo AM, Sandberg K, Tuppurainen T, Mattila K, Aalto A, Anttila VJ, Estlander C, Hamalainen M, Jalkanen M, Kanerva M, Kuutamo T, Lappalainen T, Mattila P, Pipping D, Ratia M, Sammalkorpi K, Simons L, Tommila P, Totterman I, Lehtinen P, Torvinen S, Eklund M, Fellman M, Mikkola J, Haapaniemi L, Junka A, Jakobsson A, Leppaaho-Lakka J, Patsi S, Rummukainen M, Tiitinen T, Liikka M, Hamalainen S, Koivula I, Rissanen AM, Ruotsalainen E, Terasvirta H, Hannola K, Marttinen T, Palosara J, Pietikainen R, Kaukoniemi U, Nurkkala-Pitko T, Broas M, Isojarvi J, Jagerroos H, Jankala E, Niemi P, Poyry S, Raisanen L, Leukka M, Dahl S, Ijas P, Karkkainen P, Vuorinen S, Heikkila H, Kaija T, Teirila I, Haapala J, Harkonen M, Reiman A, Salonen J, Sarkkinen H, Sihvola H, Turunen P, Taskila H, Virranniemi L, Huttunen S, Rintala E, Uusitalo-Seppala R, Pulli T, Sistonen A, Panttila A, Saikku J, Tapanainen M, Lumio J, Sinkkonen J, Routamaa M, Terho K, Elomaa N, Eriksen-Neuman B. Benchmarking antibiotic use in Finnish acute care hospitals using patient case-mix adjustment. J Antimicrob Chemother 2011; 66:2651-4. [DOI: 10.1093/jac/dkr333] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Reiman A, Srinivasan V, Barone G, Last JI, Wootton LL, Davies EG, Verhagen MM, Willemsen MA, Weemaes CM, Byrd PJ, Izatt L, Easton DF, Thompson DJ, Taylor AM. Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours. Br J Cancer 2011; 105:586-91. [PMID: 21792198 PMCID: PMC3170966 DOI: 10.1038/bjc.2011.266] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background: Immunodeficiency in ataxia telangiectasia (A-T) is less severe in patients expressing some mutant or normal ATM kinase activity. We, therefore, determined whether expression of residual ATM kinase activity also protected against tumour development in A-T. Methods: From a total of 296 consecutive genetically confirmed A-T patients from the British Isles and the Netherlands, we identified 66 patients who developed a malignant tumour; 47 lymphoid tumours and 19 non-lymphoid tumours were diagnosed. We determined their ATM mutations, and whether cells from these patients expressed any ATM with residual ATM kinase activity. Results: In childhood, total absence of ATM kinase activity was associated, almost exclusively, with development of lymphoid tumours. There was an overwhelming preponderance of tumours in patients <16 years without kinase activity compared with those with some residual activity, consistent with a substantial protective effect of residual ATM kinase activity against tumour development in childhood. In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part of the A-T phenotype. Conclusion: Overall, a spectrum of tumour types is associated with A-T, consistent with involvement of ATM in different mechanisms of tumour formation. Tumour type was influenced by ATM allelic heterogeneity, residual ATM kinase activity and age.
Collapse
Affiliation(s)
- A Reiman
- School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Yee D, Butts C, Chu Q, Fenton D, Joy A, Reiman A, Smylie M, Roa W. Phase II Trial of Consolidation Chest Radiotherapy for Extensive Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
16
|
Bitter M, Hill K, Gates D, Monticello D, Neilson H, Reiman A, Roquemore AL, Morita S, Goto M, Yamada H, Rice JE. Objectives and layout of a high-resolution x-ray imaging crystal spectrometer for the large helical device. Rev Sci Instrum 2010; 81:10E328. [PMID: 21034026 DOI: 10.1063/1.3490016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A high-resolution x-ray imaging crystal spectrometer, whose concept was tested on NSTX and Alcator C-Mod, is being designed for the large helical device (LHD). This instrument will record spatially resolved spectra of helium-like Ar(16+) and will provide ion temperature profiles with spatial and temporal resolutions of <2 cm and ≥10 ms, respectively. The spectrometer layout and instrumental features are largely determined by the magnetic field structure of LHD. The stellarator equilibrium reconstruction codes, STELLOPT and PIES, will be used for the tomographic inversion of the spectral data.
Collapse
Affiliation(s)
- M Bitter
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Yee D, Chu Q, Butts C, Joy A, Fenton D, Smylie M, Reiman A, Roa W. 77 PHASE 1 DOSE ESCALATION TRIAL OF LIMITED FIELD HYPOFRACTIONATED THORACIC RADIOTHERAPY FOR LIMITED STAGE SMALL CELL LUNG CANCER. Radiother Oncol 2009. [DOI: 10.1016/s0167-8140(12)72464-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Staples ER, McDermott EM, Reiman A, Byrd PJ, Ritchie S, Taylor AMR, Davies EG. Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol 2008; 153:214-20. [PMID: 18505428 DOI: 10.1111/j.1365-2249.2008.03684.x] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Immunodeficiency affects over half of all patients with ataxia telangiectasia (A-T) and when present can contribute significantly to morbidity and mortality. A retrospective review of clinical history, immunological findings, ataxia telangiectasia mutated (ATM) enzyme activity and ATM mutation type was conducted on 80 consecutive patients attending the National Clinic for Ataxia Telangiectasia, Nottingham, UK between 1994 and 2006. The aim was to characterize the immunodeficiency in A-T and determine its relationship to the ATM mutations present. Sixty-one patients had mutations resulting in complete loss of ATM kinase activity (group A) and 19 patients had leaky splice or missense mutations resulting in residual kinase activity (group B). There was a significantly higher proportion of patients with recurrent sinopulmonary infections in group A compared with group B (31 of 61 versus four of 19 P = 0.03) and a greater need for prophylactic antibiotics (30 of 61 versus one of 19 P = 0.001). Comparing group A with group B patients, 25 of 46 had undetectable/low immunoglobulin A (IgA) levels compared with none of 19; T cell lymphopenia was found in 28 of 56 compared with one of 18 and B cell lymphopenia in 35 of 55 compared with four of 18 patients (P = 0.00004, 0.001 and 0.003 respectively). Low IgG2 subclass levels and low levels of antibodies to pneumococcal polysaccharide were more common in group A than group B (16 of 27 versus one of 11 P = 0.01; 34/43 versus six of 17 P = 0.002) patients. Ig replacement therapy was required in 10 (12.5%) of the whole cohort, all in group A. In conclusion, A-T patients with no ATM kinase activity had a markedly more severe immunological phenotype than those expressing low levels of ATM activity.
Collapse
Affiliation(s)
- E R Staples
- Department of Immunology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | | | | | | | | | | | | |
Collapse
|
19
|
Reiman A. Stabilization of the vertical mode in tokamaks by localized nonaxisymmetric fields. Phys Rev Lett 2007; 99:135007. [PMID: 17930604 DOI: 10.1103/physrevlett.99.135007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2007] [Indexed: 05/25/2023]
Abstract
Vertical instability of a tokamak plasma can be controlled by nonaxisymmetric magnetic fields localized near the plasma edge at the bottom and top of the torus. The required magnetic fields can be produced by a relatively simple set of parallelogram-shaped coils.
Collapse
Affiliation(s)
- A Reiman
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| |
Collapse
|
20
|
Campean V, Neureiter D, Varga I, Runk F, Reiman A, Garlichs C, Achenbach S, Nonnast-Daniel B, Amann K. Atherosclerosis and Vascular Calcification in Chronic Renal Failure. Kidney Blood Press Res 2006; 28:280-9. [PMID: 16534222 DOI: 10.1159/000090182] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Cardiovascular complications are a major clinical problem in patients with chronic kidney disease and end-stage renal failure; cardiac death accounts for approximately 40-50% of all deaths in these patients. Death from cardiovascular causes is up to 20 times more common in uremic patients than in the general population with the risk being even higher than in patients with diabetes mellitus. A high rate of myocardial infarction and excessive cardiac mortality have repeatedly been documented in patients with kidney disease and renal failure. Not only is the prevalence of myocardial infarction high, but also the case fatality rate is significantly higher in uremic patients with and without diabetes, respectively, compared to nonuremic patients. This is of particular interest since the prevalence of coronary atheroma in uremic patients was shown to be approximately 30% by autopsy and coronary angiography studies. Thus, coronary factors, i.e. atherosclerosis, and non-coronary factors may play an important role in the genesis of cardiac complications in the renal patient. In addition, renal failure recently has also be identified as a predictor of mortality in different stages of peripheral vascular disease. In particular, marked differences in the pathogenesis, morphology and course of atherosclerosis and arteriosclerosis under the conditions of renal failure have been documented. Among others increased plaque formation and particularly higher proportion and intensity of vascular calcification have been found in clinical and autopsy studies. In addition to the so-called classical or traditional risk factors, an important role for nonclassical risk factors such as microinflammation, hyperphosphatemia and oxidative stress has been documented in patients with renal failure and is discussed in detail.
Collapse
Affiliation(s)
- V Campean
- Department of Pathology, Med. II and Med. IV, University of Erlangen-Nurnberg, Erlangen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Reiman A, Powell JE, Flavell KJ, Grundy RG, Mann JR, Parkes S, Redfern D, Young LS, Murray PG. Seasonal differences in the onset of the EBV-positive and -negative forms of paediatric Hodgkin's lymphoma. Br J Cancer 2003; 89:1200-1. [PMID: 14520445 PMCID: PMC2394289 DOI: 10.1038/sj.bjc.6601277] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
In this study, we have shown that there are seasonal differences in the onset of the (Epstein–Barr virus) EBV-positive and -negative forms of paediatric Hodgkin's lymphoma (HL). This suggests aetiological differences between the two forms of this disease. EBV-positive HL might be a rare consequence of primary EBV infection.
Collapse
Affiliation(s)
- A Reiman
- Department of Pathology, Division of Cancer Studies, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - J E Powell
- Department of Public Health & Epidemiology, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - K J Flavell
- Department of Pathology, Division of Cancer Studies, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - R G Grundy
- Department of Oncology, The Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
| | - J R Mann
- Department of Oncology, The Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
| | - S Parkes
- Department of Oncology, The Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
| | - D Redfern
- Department of Pathology, The Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, UK
| | - L S Young
- Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - P G Murray
- Department of Pathology, Division of Cancer Studies, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
- Division of Cancer Studies, The Medical School. E-mail:
| |
Collapse
|
22
|
Schmidt JA, Thomassen KI, Goldston RJ, Neilson GH, Nevins WM, Sinnis JC, Andersen P, Bair W, Barr WL, Batchelor DB, Baxi C, Berg G, Bernabei S, Bialek JM, Bonoli PT, Boozer A, Bowers D, Bronner G, Brooks JN, Brown TG, Bulmer R, Butner D, Campbell R, Casper T, Chaniotakis E, Chaplin M, Chen SJ, Chin E, Chrzanowski J, Citrolo J, Cole MJ, Dahlgren F, Davis FC, Davis J, Davis S, Diatchenko N, Dinkevich S, Feldshteyn Y, Felker B, Feng T, Fenstermacher ME, Fleming R, Fogarty PJ, Fragetta W, Fredd E, Gabler M, Galambos J, Gohar Y, Goranson PL, Greenough N, Grisham LR, Haines J, Haney S, Hassenzahl W, Heim J, Heitzenroeder PJ, Hill DN, Hodapp T, Houlberg WA, Hubbard A, Hyatt A, Jackson M, Jaeger EF, Jardin SC, Johnson J, Jones GH, Juliano DR, Junge R, Kalish M, Kessel CE, Knutson D, LaHaye RJ, Lang DD, Langley RA, Liew SL, Lu E, Mantz H, Manickam J, Mau TK, Medley S, Mikkelsen DR, Miller R, Monticello D, Morgan D, Moroz P, Motloch C, Mueller J, Myatt L, Nelson BE, Neumeyer CL, Nilson D, O'Conner T, Pearlstein LD, Peebles WA, Pelovitz M, Perkins FW, Perkins LJ, Petersen D, Pillsbury R, Politzer PA, Pomphrey N, Porkolab M, Posey A, Radovinsky A, Raftopoulis S, Ramakrishnan S, Ramos J, Rauch W, Ravenscroft D, Redler K, Reiersen WT, Reiman A, Reis E, Rewoldt G, Richards DJ, Rocco R, Rognlien TD, Ruzic D, Sabbagh S, Sapp J, Sayer RO, Scharer JE, Schmitz L, Schnitz J, Sevier L, Shipley SE, Simmons RT, Slack D, Smith GR, Stambaugh R, Steill G, Stevenson T, Stoenescu S, Onge KTS, Stotler DP, Strait T, Strickler DJ, Swain DW, Tang W, Tuszewski M, Ulrickson MA, VonHalle A, Walker MS, Wang C, Wang P, Warren J, Werley KA, West WP, Williams F, Wong R, Wright K, Wurden GA, Yugo JJ, Zakharov L, Zbasnik J. The design of the Tokamak Physics Experiment (TPX). J Fusion Energ 1993. [DOI: 10.1007/bf01079667] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Reiman A. Physician gets marketing assistance from progressive hospital. J Med Pract Manage 1987; 2:103-9. [PMID: 10281422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Increasing a physician's office volume is beneficial to the hospital where the physician practices. Hospital assistance in marketing the physician's services can therefore be rewarding to both parties and enhance physician allegiance to the hospital providing the support. A theoretical model for such marketing support is reviewed step by step, through analysis of existing practice, targeting markets, selecting desirable improvements and changes, and advertising the practice. The successful results are profiled.
Collapse
|